Related Experiment Video

Updated: Feb 19, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Maria Luisa Gasparri1,2, Erlisa Bardhi1, Ilary Ruscito1

  • 1Department of Gynecology, Obstetrics and Urology, "Sapienza" University of Rome, Rome, Italy.

Geburtshilfe Und Frauenheilkunde
|November 3, 2017
PubMed

Insights

Targeting the PI3K/AKT/mTOR pathway with mTor inhibitors offers a promising strategy to improve outcomes for ovarian cancer patients. These targeted therapies aim to reduce tumor growth and minimize side effects, addressing the limitations of conventional treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian cancer exhibits high recurrence rates and low survival, necessitating novel therapeutic strategies beyond conventional treatments.
  • The PI3K/AKT/mTOR intracellular signaling pathway is frequently dysregulated in various cancers, including ovarian cancer, and plays a critical role in cell growth, proliferation, and angiogenesis.
  • mTOR proteins represent a key target for therapeutic intervention due to their central role in cellular proliferation.

Purpose of the Study:

  • To investigate the potential of targeting the PI3K/AKT/mTOR pathway as a specific therapeutic approach for ovarian cancer.
  • To evaluate the role of mTor inhibitors in counteracting tumor growth and improving survival in ovarian cancer.
  • To assess the safety and efficacy of mTor inhibitors, both as monotherapy and in combination with conventional treatments.

Main Methods:

  • Review of translational and clinical research on molecular targets in ovarian cancer.
  • Analysis of the PI3K/AKT/mTOR pathway's involvement in ovarian tumorigenesis.
  • Examination of clinical trial data assessing mTor inhibitors in ovarian cancer patients.

Main Results:

  • Dysregulation of the PI3K/AKT/mTOR pathway is implicated in ovarian cancer development and progression.
  • mTor inhibitors have shown promise in preclinical and clinical settings for other cancers.
  • Ongoing clinical trials are evaluating the safety and oncologic outcomes of mTor inhibitors in ovarian cancer.

Conclusions:

  • mTor inhibitors represent a potential targeted therapy for ovarian cancer, offering an alternative to conventional treatments.
  • Further clinical investigation, including Phase I and II studies, is crucial to determine the optimal use of mTor inhibitors in ovarian cancer treatment regimens.
  • Combination therapies involving mTor inhibitors with chemotherapy or other targeted agents warrant continued evaluation for enhanced efficacy.
Keywords:
PI3K/AKT/mTOReverolimusmTOR inhibitorsovarian cancertarget therapytemsirolimus

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K